Do analysts recommend BCLI or PDSB?

PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 1,124.66%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher valuation & earnings, BCLI or PDSB?

PDS Biotechnology is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.64 N/A PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A

Is BCLI or PDSB more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% PDS Biotechnology N/A -346.02% -102.36%

Do analysts rate BCLI or RNXT?

RenovoRx has a consensus target price of $8.50, suggesting a potential upside of 882.32%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Does the media prefer BCLI or RNXT?

In the previous week, Brainstorm Cell Therapeutics and Brainstorm Cell Therapeutics both had 1 articles in the media. RenovoRx's average media sentiment score of 1.89 beat Brainstorm Cell Therapeutics' score of 0.67 indicating that RenovoRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainstorm Cell Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend BCLI or NNVC?

NanoViricides has a consensus price target of $6.00, indicating a potential upside of 242.86%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts clearly believe NanoViricides is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better earnings & valuation, BCLI or NNVC?

NanoViricides is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.64 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is BCLI or NNVC more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% NanoViricides N/A -87.90% -78.69%

Do analysts rate BCLI or IZTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, BCLI or IZTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.64 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is BCLI or IZTC more profitable?

Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% Invizyne Technologies N/A N/A N/A

Do analysts rate IXHL or BCLI?

Incannex Healthcare presently has a consensus target price of $18.00, indicating a potential upside of 467.82%. Given Incannex Healthcare's higher probable upside, analysts plainly believe Incannex Healthcare is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is IXHL or BCLI more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% Brainstorm Cell Therapeutics N/A N/A -519.50%

Does the media favor IXHL or BCLI?

In the previous week, Incannex Healthcare and Incannex Healthcare both had 1 articles in the media. Incannex Healthcare's average media sentiment score of 1.53 beat Brainstorm Cell Therapeutics' score of 0.67 indicating that Incannex Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incannex Healthcare 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Brainstorm Cell Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Brainstorm Cell Therapeutics (BCLI) Competitors

$0.90 -0.05 (-4.91%)

As of 07/17/2026 03:42 PM Eastern

Compare

BCLI vs. PDSB, RNXT, NNVC, IZTC, and IXHL

Should you buy Brainstorm Cell Therapeutics stock or one of its competitors? MarketBeat compares Brainstorm Cell Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Brainstorm Cell Therapeutics include PDS Biotechnology (PDSB), RenovoRx (RNXT), NanoViricides (NNVC), Invizyne Technologies (IZTC), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry.

How does Brainstorm Cell Therapeutics compare to PDS Biotechnology?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

In the previous week, Brainstorm Cell Therapeutics had 1 more articles in the media than PDS Biotechnology. MarketBeat recorded 1 mentions for Brainstorm Cell Therapeutics and 0 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 1.89 beat Brainstorm Cell Therapeutics' score of 0.67 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Brainstorm Cell Therapeutics	Positive
PDS Biotechnology	Very Positive

PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 1,124.66%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Brainstorm Cell Therapeutics' return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
PDS Biotechnology	N/A	-346.02%	-102.36%

PDS Biotechnology is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Brainstorm Cell Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market.

Summary

PDS Biotechnology beats Brainstorm Cell Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to RenovoRx?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Brainstorm Cell Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, RenovoRx has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

RenovoRx has a consensus target price of $8.50, suggesting a potential upside of 882.32%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Comparatively, 9.4% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Brainstorm Cell Therapeutics and Brainstorm Cell Therapeutics both had 1 articles in the media. RenovoRx's average media sentiment score of 1.89 beat Brainstorm Cell Therapeutics' score of 0.67 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

RenovoRx has higher revenue and earnings than Brainstorm Cell Therapeutics. RenovoRx is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
RenovoRx	$1.12M	34.81	-$11.17M	-$0.33	N/A

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
RenovoRx	-823.98%	-135.03%	-101.92%

Summary

RenovoRx beats Brainstorm Cell Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to NanoViricides?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

NanoViricides is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

NanoViricides has a consensus price target of $6.00, indicating a potential upside of 242.86%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts clearly believe NanoViricides is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Brainstorm Cell Therapeutics had 1 more articles in the media than NanoViricides. MarketBeat recorded 1 mentions for Brainstorm Cell Therapeutics and 0 mentions for NanoViricides. Brainstorm Cell Therapeutics' average media sentiment score of 0.67 beat NanoViricides' score of 0.48 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Brainstorm Cell Therapeutics	Positive
NanoViricides	Neutral

Brainstorm Cell Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
NanoViricides	N/A	-87.90%	-78.69%

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Comparatively, 3.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Brainstorm Cell Therapeutics has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

Summary

NanoViricides beats Brainstorm Cell Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Invizyne Technologies?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Invizyne Technologies	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Brainstorm Cell Therapeutics had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Brainstorm Cell Therapeutics and 0 mentions for Invizyne Technologies. Brainstorm Cell Therapeutics' average media sentiment score of 0.67 beat Invizyne Technologies' score of 0.00 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Brainstorm Cell Therapeutics	Positive
Invizyne Technologies	Neutral

Summary

Brainstorm Cell Therapeutics beats Invizyne Technologies on 5 of the 6 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Incannex Healthcare presently has a consensus target price of $18.00, indicating a potential upside of 467.82%. Given Incannex Healthcare's higher probable upside, analysts plainly believe Incannex Healthcare is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Incannex Healthcare has a beta of 6.95, indicating that its stock price is 595% more volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Incannex Healthcare and Incannex Healthcare both had 1 articles in the media. Incannex Healthcare's average media sentiment score of 1.53 beat Brainstorm Cell Therapeutics' score of 0.67 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incannex Healthcare	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	421.61	-$46.88M	-$1.55	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A

Summary

Incannex Healthcare beats Brainstorm Cell Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Brainstorm Cell Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCLI vs. The Competition

Export

Metric	Brainstorm Cell Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.89M	$3.69B	$6.89B	$12.44B
Dividend Yield	N/A	2.16%	2.67%	8.84%
P/E Ratio	-0.27	20.85	27.14	23.91
Price / Sales	N/A	304.43	524.01	90.57
Price / Cash	N/A	142.33	51.46	60.07
Price / Book	-0.66	8.26	10.69	6.18
Net Income	-$11.62M	$23.83M	$3.59B	$331.95M
7 Day Performance	-17.02%	-3.47%	-2.18%	-2.05%
1 Month Performance	3.67%	2.58%	1.63%	-2.14%
1 Year Performance	4.82%	45.93%	25.58%	17.28%

Brainstorm Cell Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCLI Brainstorm Cell Therapeutics	0.5272 of 5 stars	$0.90 -4.9%	N/A	-23.4%	$9.89M	N/A	N/A	40	News Coverage
PDSB PDS Biotechnology	3.42 of 5 stars	$0.75 +0.9%	$9.00 +1,096.8%	-38.8%	$41.67M	N/A	N/A	20	Positive News
RNXT RenovoRx	4.1802 of 5 stars	$0.85 -6.9%	$8.50 +900.0%	-33.4%	$41.15M	$1.12M	N/A	6	News Coverage Positive News Analyst Upgrade Gap Up
NNVC NanoViricides	1.7531 of 5 stars	$1.77 +7.3%	$6.00 +239.0%	+6.7%	$40.68M	N/A	N/A	20	Positive News
IZTC Invizyne Technologies	N/A	$6.37 -8.6%	N/A	-37.2%	$39.83M	N/A	N/A	29	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCLI) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brainstorm Cell Therapeutics (BCLI) Competitors

BCLI vs. PDSB, RNXT, NNVC, IZTC, and IXHL

How does Brainstorm Cell Therapeutics compare to PDS Biotechnology?

Summary

How does Brainstorm Cell Therapeutics compare to RenovoRx?

Summary

How does Brainstorm Cell Therapeutics compare to NanoViricides?

Summary

How does Brainstorm Cell Therapeutics compare to Invizyne Technologies?

Summary

How does Brainstorm Cell Therapeutics compare to Incannex Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI vs. The Competition

Brainstorm Cell Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brainstorm Cell Therapeutics (BCLI) Competitors

BCLI vs. PDSB, RNXT, NNVC, IZTC, and IXHL

How does Brainstorm Cell Therapeutics compare to PDS Biotechnology?

Does the media favor BCLI or PDSB?

Do analysts recommend BCLI or PDSB?

Is BCLI or PDSB more profitable?

Which has higher valuation & earnings, BCLI or PDSB?

Do institutionals and insiders hold more shares of BCLI or PDSB?

Which has more risk & volatility, BCLI or PDSB?

Summary

How does Brainstorm Cell Therapeutics compare to RenovoRx?

Which has more risk & volatility, BCLI or RNXT?

Do analysts rate BCLI or RNXT?

Do institutionals & insiders hold more shares of BCLI or RNXT?

Does the media prefer BCLI or RNXT?

Which has higher earnings & valuation, BCLI or RNXT?

Is BCLI or RNXT more profitable?

Summary

How does Brainstorm Cell Therapeutics compare to NanoViricides?

Which has better earnings & valuation, BCLI or NNVC?

Do analysts recommend BCLI or NNVC?

Does the media prefer BCLI or NNVC?

Is BCLI or NNVC more profitable?

Do insiders & institutionals believe in BCLI or NNVC?

Which has more volatility and risk, BCLI or NNVC?

Summary

How does Brainstorm Cell Therapeutics compare to Invizyne Technologies?

Do analysts rate BCLI or IZTC?

Is BCLI or IZTC more profitable?

Which has stronger earnings and valuation, BCLI or IZTC?

Do insiders and institutionals hold more shares of BCLI or IZTC?

Does the media refer more to BCLI or IZTC?

Summary

How does Brainstorm Cell Therapeutics compare to Incannex Healthcare?

Do analysts rate IXHL or BCLI?

Which has more volatility & risk, IXHL or BCLI?

Do insiders & institutionals have more ownership in IXHL or BCLI?

Does the media favor IXHL or BCLI?

Is IXHL or BCLI more profitable?

Which has higher earnings and valuation, IXHL or BCLI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI vs. The Competition

Brainstorm Cell Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools